GV1001 for Moderate to Severe Alzheimer's Disease (NCT05303701)

GV1001 for Moderate to Severe Alzheimer's Disease

Overview

GV1001 for Moderate to Severe Alzheimer's Disease

Overview

NCT05303701 is a pivotal Phase 3 clinical trial conducted by Samsung Pharmaceutical Co., Ltd. evaluating the efficacy and safety of GV1001, a telomerase-derived peptide vaccine, for the treatment of moderate to severe Alzheimer's disease. This multi-center, randomized, double-blind, placebo-controlled trial represents a novel approach to AD treatment by targeting cellular senescence and promoting neuroprotection through telomerase-mediated mechanisms["@cho2019"][@kim2020].

GV1001 represents a fundamentally different therapeutic strategy from the anti-amyloid antibodies that have dominated recent AD drug development. Rather than directly targeting amyloid or tau pathology, GV1001 aims to restore cellular function by activating telomerase, thereby addressing what many researchers consider a fundamental upstream contributor to neurodegeneration: cellular senescence and impaired neural stem cell function["@lee2023"].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT05303701 |
| Official Title | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Administration of GV1001 1.12 mg/Day in Patients With Moderate to Severe Alzheimer Disease |
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Sponsor | Samsung Pharmaceutical Co., Ltd. |
| Enrollment | 750 participants (Estimated) |
| Study Type | Interventional |
| Allocation | Randomized |
| Intervention Model | Parallel |
| Masking | Double-blind |
| Start Date | July 1, 2027 |
| Primary Completion | July 1, 2031 |
| Last Updated | February 23, 2026 |

Conditions and Eligibility

Conditions Studied

• Moderate Alzheimer's Disease
• Severe Alzheimer's Disease
• Alzheimer's Disease with Behavioral Symptoms

Inclusion Criteria

• Age 60-85 years
• Confirmed diagnosis of probable AD meeting NINCDS-ADRDA criteria
• MMSE score between 6-20 (moderate to severe disease)
• Clinical Dementia Rating (CDR) score of 2 or 3
• Neuroimaging consistent with AD (CT or MRI)
• Stable AD medications for at least 30 days
• Caregiver availability for study participation

Exclusion Criteria

• Other neurological diseases causing dementia
• Major psychiatric disorders
• Significant medical conditions affecting cognition
• Contraindications to immunotherapy
• Prior participation in GV1001 trials

Scientific Background

Cellular Senescence in Alzheimer's Disease

Cellular senescence is increasingly recognized as a key contributor to Alzheimer's disease pathogenesis. Senescent cells accumulate in the aging brain and exhibit a pro-inflammatory secretome (the senescence-associated secretory phenotype, SASP) that contributes to chronic neuroinflammation, neural stem cell dysfunction, and progressive neurodegeneration[@zhao2023].

Key features of cellular senescence in AD include:

• Telomere shortening: Accelerated telomere attrition in neurons and glia
• Senescent cell accumulation: Increased numbers of senescent astrocytes and microglia
• SASP-mediated inflammation: Pro-inflammatory cytokines that drive neuroinflammation
• Stem cell impairment: Impaired neurogenesis in the hippocampal niche

The Telomerase Approach

Telomerase is a ribonucleoprotein enzyme that maintains telomere length and has been shown to have protective effects in neurons beyond its canonical role in cellular aging. Research has demonstrated that telomerase:

The telomerase reverse transcriptase (TERT) component of telomerase has been shown to translocate to the nucleus in neurons and exert transcription-independent neuroprotective effects, making it an attractive therapeutic target[@mattson2003].

GV1001 Mechanism of Action

GV1001 is a 16-amino acid peptide (KRVKWLRRMVRKRLVK) derived from the active site of the human telomerase reverse transcriptase (hTERT). This peptide is designed to:

The mechanism differs fundamentally from passive antibody therapies:

• Active immunization triggers the patient's own immune system
• Produces sustained immune response with long-term effects
• May involve multiple mechanisms beyond direct antigen clearance

Preclinical Evidence

Preclinical studies in the 5xFAD mouse model demonstrated[@cho2019]:

• Reduced amyloid plaques: Significant decrease in amyloid burden
• Improved cognitive function: Better performance in maze and memory tests
• Enhanced neurogenesis: Increased hippocampal neuron generation
• Reduced neuroinflammation: Decreased pro-inflammatory markers
• Improved synaptic markers: Restoration of synaptic proteins

Clinical Development History

GV1001 has undergone extensive clinical development:

| Phase | Indication | Key Findings |
|-------|------------|--------------|
| Phase 1/2 | Cancer (melanoma, lung) | Safety established, immunogenic |
| Phase 1/2 | AD | Dose-dependent immune response, good safety |
| Phase 2 | Moderate AD | Positive cognitive signals |
| Phase 3 | Moderate-severe AD | Currently enrolling |

Study Design

Primary Objectives

Investigational Arms

• GV1001 Active: 1.12 mg subcutaneous injection daily
• Placebo: Matching vehicle injection daily

Treatment Duration

• 24-week treatment period
• Assessment visits at baseline, weeks 4, 12, 24, and follow-up

Key Assessments

• Cognitive testing (SIB, MMSE)
• Global assessment (CIBIC-plus, CDR)
• Functional assessment (ADCS-ADL)
• Safety monitoring
• Biomarker studies

Outcome Measures

Primary Endpoints

Secondary Endpoints

• Change in MMSE score
• Change in ADCS-ADL score
• Change in neuropsychiatric inventory (NPI)
• Time to disease progression
• Biomarker changes

Safety Endpoints

• Treatment-emergent adverse events
• Serious adverse events
• Laboratory and vital sign changes
• Anti-drug antibody formation

Clinical Significance

Novel Therapeutic Approach

GV1001 represents a fundamentally different approach to AD treatment:

| Approach | Target | Examples | Status |
|----------|--------|----------|--------|
| Anti-amyloid antibodies | Amyloid plaques | Lecanemab, Donanemab | Approved |
| Anti-tau antibodies | Tau tangles | Various in development | Phase 2/3 |
| Neurotransmitter modulators | Symptomatic | Donepezil, Memantine | Approved |
| Telomerase vaccine | Cellular senescence | GV1001 | Phase 3 |

By targeting cellular senescence and supporting neural stem cell function, GV1001 addresses mechanisms that may be upstream of classical amyloid and tau pathology[@lee2023].

Moderate to Severe AD Population

This trial specifically targets patients with moderate to severe AD, a population with limited therapeutic options:

• Current approved treatments (donepezil, memantine) provide only modest symptomatic benefit
• Anti-amyloid antibodies have primarily been studied in early disease stages
• There is a significant unmet need for disease-modifying treatments in later-stage patients

Comparison to Other Immunotherapeutic Approaches

Active immunization approaches for AD include[@gonzalez2023]:

| Vaccine | Target | Approach | Stage |
|---------|--------|----------|-------|
| GV1001 | TERT | Telomerase activation | Phase 3 |
| ACI-35 | Phospho-tau | Liposome vaccine | Phase 1/2 |
| UB-311 | Amyloid-beta | Active immunization | Phase 2 |
| CAD106 | Amyloid-beta | Active immunization | Phase 2 |

Active vaccines offer potential advantages:

• Lower cost of administration
• Sustained immune response
• Potential for broader immune effects

Safety Profile

Preclinical and Early Clinical Data

Based on previous clinical trials, the expected safety profile includes:

Common (Expected) Adverse Events:

• Injection site reactions (redness, swelling)
• Mild flu-like symptoms
• Transient headache

• Gastrointestinal symptoms
• Fatigue

Monitoring Protocol

The trial includes:

• Regular physical and neurological examinations
• Laboratory monitoring
• Adverse event collection
• Immunogenicity assessment
• ECG monitoring

Future Directions

If Successful

Positive results would represent a paradigm shift in AD treatment:

Biomarker Development

The trial may contribute to understanding:

• Telomere length as a biomarker
• SASP markers as treatment response indicators
• Neuroinflammatory biomarkers
• Imaging correlates of treatment response

Combination Potential

Given its novel mechanism, GV1001 may be combinable with:

• Standard cholinesterase inhibitors
• [Memantine](/therapeutics/memantine)
• Future disease-modifying therapies

Immunologic Mechanism Deep Dive

GV1001 Peptide Structure

GV1001 (KRVKWLRRMVRKRLVK) is a 16-amino acid peptide derived from the active site of human telomerase reverse transcriptase (hTERT)[@kim2020]. The peptide is designed to:

Cellular Immune Response

The cellular immune response induced by GV1001 involves multiple populations[@kim2020]:

| Cell Type | Function | Key Mediators |
|----------|----------|---------------|
| CD4+ Helper T cells | Antigen recognition | IFN-γ, IL-2, IL-4 |
| CD8+ Cytotoxic T cells | Target cell killing | Perforin, Granzyme B |
| B cells | Antibody production | IgG, IgM |
| NK cells | Innate immunity | IFN-γ |

Immunogenicity Optimization

The immunogenicity of GV1001 is enhanced by:

• Carrier protein: KLH (keyhole limpet hemocyanin) conjugation
• Emulsification: Montanide ISA 51 adjuvant
• Boosting: Multiple immunizations required for sustained response

Clinical Trial Design Deep Dive

Assessment Schedule

Comprehensive schedule includes:

| Visit | Timing | Key Assessments |
|-------|--------|-----------------|
| Screening | Days -28 to 0 | Medical history, cognitive testing |
| Baseline | Day 0 | SIB, MMSE, CIBIC, safety |
| Week 4 | Day 28 | SIB, MMSE, safety |
| Week 12 | Day 84 | SIB, MMSE, CIBIC, safety |
| Week 24 | Day 168 | SIB, MMSE, CIBIC, safety |
| Follow-up | Day 196 | Safety, long-term effects |

Statistical Analysis

Primary efficacy analysis uses:

• Population: Intent-to-treat (ITT)
• Method: Mixed model for repeated measures (MMRM)
• Missing data: Multiple imputation
• Alpha: 0.05 (two-sided)

Patient Population Deep Dive

Moderate AD (MMSE 10-20)

Moderate AD patients represent a substantial portion of the AD population:

| Feature | Value |
|---------|-------|
| Prevalence | ~40% of AD cases |
| Age | 70-80 years (median) |
| Disease duration | 3-6 years |
| CDR | 2 (moderate) |

Severe AD (MMSE <10)

Severe AD patients represent a challenging population:

| Feature | Value |
|---------|-------|
| Prevalence | ~20% of AD cases |
| Care needs | Extensive |
| Life expectancy | Reduced |
| Treatment options | Limited |

This population has historically been excluded from most clinical trials. GV1001's novel mechanism may offer benefits at advanced disease stages.

Biomarker Development

Telomere Length as Biomarker

Telomere length may serve as a treatment response biomarker:

| Measure | Method | Utility |
|---------|--------|---------|
| Leukocyte TL | qPCR | Population screening |
| Tissue TL | FISH | Research |
| Telomere ratio | Various | Response marker |

Studies have shown shortened telomere length in AD patients correlates with disease severity.

Neuroinflammatory Markers

Treatment response may be assessed through inflammatory biomarkers:

| Marker | Source | Expected Change |
|--------|--------|------------------|
| IL-6 | Serum | Decrease |
| TNF-α | Serum | Decrease |
| S100B | CSF | Decrease |

Comparison with Other Immunotherapeutics

GV1001 vs Passive Antibodies

| Feature | GV1001 | Passive Antibodies |
|---------|--------|-------------------|
| Administration | Subcutaneous | Intravenous |
| Immune response | Active | Passive |
| Duration | Long-lasting | Finite |
| Boosters needed | Yes | No |
| Cost | Lower | Higher |

GV1001 vs Other Active Vaccines

| Vaccine | Target | Stage | Mechanism |
|---------|--------|-------|-----------|
| GV1001 | TERT | Phase 3 | Telomerase activation |
| ACI-35 | Phospho-tau | Phase 1/2 | Tau immunotherapy |
| UB-311 | Amyloid-β | Phase 2 | Amyloid immunotherapy |
| CAD106 | Amyloid-β | Phase 2 | Amyloid immunotherapy |

Clinical and Regulatory Considerations

Trial Sites and Recruitment

The trial requires:

• Sites: 100+ global sites
• Recruitment: 24 months
• Enrollment rate: ~30 participants/month
• Retention: Critical for completion

Regulatory Pathway

Based on Phase 3 design:

| Milestone | Timeline |
|-----------|-----------|
| Topline data | 2031 |
| NDA submission | 2032 |
| Potential approval | 2033 |

Priority review may be available given the moderate-to-severe population unmet need.

Conclusion

NCT05303701 represents an important step in AD therapeutic development:

The success of GV1001 would validate telomerase-mediated neuroprotection as a therapeutic approach in neurodegeneration.

Expert Perspective on Telomerase in Neurobiology

The scientific rationale for targeting telomerase in AD includes:

Future Research Directions

Positive results would enable:

Operational Considerations for Success

Key factors for successful development:

| Factor | Description |
|--------|------------|
| Efficacy signal | Cognitive preservation at 6 months |
| Safety profile | No unexpected concerns |
| Biomarker correlation | Telomere/immune markers |
| Caregiver benefit | Reduced burden |

Related Resources

• [GV1001](/entities/gv1001)
• [Telomerase](/entities/telomerase-reverse-transcriptase)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Cellular Senescence](/mechanisms/cellular-senescence-neurodegeneration)
• [Active Immunotherapy](/mechanisms/alzheimers-immunotherapy)
• [Clinical Trials Overview](/clinical-trials/overview)
• [Drug Development Pipeline](/clinical-trials/drug-pipeline)

External Links

• [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT05303701)
• [Samsung Pharmaceutical](https://www.samsungpharm.com)
• [Alzheimer's Association](https://www.alz.org)
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu)

References